secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001193125-23-082174
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha reports Q4 net loss $55.7M; cash $87.9M; progress on Rett and GAN trials
-------------------------------------------------------------------------------

- Net loss Q4 2022: $55.7M ($0.99/shr) vs $50.4M Q4 2021; full year loss $166.0M vs $174.5M.
- Cash $87.9M at 12/31/22; expected to fund operations into Q1 2024.
- TSHA-102: screening started for REVEAL trial; first adult dosing H1 2023; initial safety data expected H1 2023.
- TSHA-120: FDA suggests alternative trial designs; formal meeting request planned Q2 2023.
- Non-cash impairment charge of $36.4M in Q4 2022 for NC manufacturing facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523082174/0001193125-23-082174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523082174/d486592d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-082174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer